Health, treatment and health care resources consumption profile among Spanish adults with diabetes and chronic obstructive pulmonary disease

Primary Care Diabetes

Volumn 3, Issue 3, 2009, Pages 141-148

  Jimenez Garcia, Rodrigo ^a   de Miguel Díez, Javier ^b   Rejas Gutierrez, Javier ^c   Martín Centeno, Antonio ^c   Gobartt Vázquez, Elena ^d   Hernandez Barrera, Valentin ^a   Gil de Miguel, Angel ^a   Carrasco Garrido, Pilar ^a  

^a Dpto Ciencias de la Salud URJC   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c PFIZER INC   (United States)

^d Departamento Médico Boehringer Ingelheim España   (Spain)

Author keywords

COPD; Diabetes; Health care resources; Quality of life; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; MUCOLYTIC AGENT; PNEUMOCOCCUS VACCINE; THEOPHYLLINE;

ADULT; AGE DISTRIBUTION; AGED; AIRWAY OBSTRUCTION; ANXIETY; ARTICLE; BIVARIATE ANALYSIS; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG USE; EDUCATIONAL STATUS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBESITY; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SEX RATIO; SHORT FORM 12; SITTING; SMOKING; SOCIAL ASPECT; SPAIN;

ADULT; AGED; BODY MASS INDEX; DEMOGRAPHY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPAIN;

EID: 70350006682     PISSN: 17519918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcd.2009.06.005     Document Type: Article

References (50)

1. Mannino D.M., Thorn D., Swensen A., and Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 32 (2008) 962-969
2. Rana J.S., Mittleman M.A., Sheikh J., Hu F.B., Manson J.E., Colditz G.A., et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 27 (2004) 2478-2484
3. Loukides S., and Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 63 (1996) 170-173
4. Antonelli I.R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 10 (1997) 2794-2800
5. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 353 (1999) 1649-1652
6. Hotamisligil G.S. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245 (1999) 621-625
7. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
8. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. 34 Suppl. (2001) 50S-59S
9. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
10. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC) potsdam study. Diabetes 52 (2003) 812-817
11. Thorand B., Lowel H., Schneider A., Kolb H., Meisinger C., Frohlich M., et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study 1984-1998. Arch. Intern. Med. 163 (2003) 93-99
12. Hu F.B., Meigs J.B., Li T.Y., Rifai N., and Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53 (2004) 693-700
13. Creutzberg E.C., and Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur. Respir. J. 22 Suppl. 46 (2004) 76S-80S
14. Sevenoaks M.J., and Stockley R.A. Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype?. Respir. Res. 7 (2006) 70
15. Baker E.H., Janaway C.H., Philips B.J., Brennan A.L., Baines D.L., Wood D.M., et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61 (2006) 284-289
16. Bolton C.E., Evans M., Ionescu A.A., Edwards S.M., Morris R.H., Dunseath G., et al. Insulin resistance and inflammation-a further systemic complication of COPD. COPD 4 (2007) 121-126
17. García Carballo M., Carrasco Garrido P., Jiménez García R., Martín A., Gobartt E., and Gil A. Estudio epidemiológico para valorar la calidad de vida y el consumo de recursos sanitarios en los pacientes con enfermedad pulmonar obstructiva crónica (EPIDEPOC). Metodología y resultados iniciales. Med. Gen. 67 (2004) 485-490
18. Carrasco Garrido P., de Miguel Díez J., Rejas Gutiérrez J., Martín Centeno A., Gobartt Vázquez E., Gil de Miguel A., et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual. Life Outcomes 4 (2006) 31
19. Barberà J.A., Peces-Barba G., Agustí A.G.N., Izquierdo J.L., Monsó E., Montemayor T., and Viejo J.L. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch. Bronconeumol. 37 (2001) 297-316
20. Ware J.E., Kosinski M., and Keller S.D. A 12-item short-form health survey, construction of scales and preliminary tests of realiabity and validity. Med. Care 34 (1996) 220-233
21. Instituto Nacional de Estadística. http://www.ine.es.
22. Lazarus R., Sparrow D., and Weiss S.T. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the normative aging study. Eur. Respir. J. 12 (1998) 641-645
23. Engstrom G., and Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet. Med. 19 (2002) 167-170
24. Engstrom G., Hedblad B., Nilsson P., Wollmer P., Berglund G., and Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J. Intern. Med. 253 (2003) 574-581
25. Litonjua A.A., Lazarus R., Sparrow D., DeMolles D., and Weiss S.T. Lung function in type 2 diabetes: the normative aging study. Respir. Med. 99 (2005) 1583-1590
26. De Lucas-Ramos P., Izquierdo-Alonso J.L., Rodríguez-González Moro J.M., Bellón-Cano J.M., Ancochea-Bermúdez J., Calle-Rubio M., et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch. Bronconeumol. 44 (2008) 233-238
27. Curkendall S.M., Lanes S., de Luise C., Stang M.R., Jones J.K., She D., et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 21 (2006) 803-813
28. Wood-Baker R.R., Gibson P.G., Hannay M., Walters E.H., and Walters J.A. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 1 (2005) CD001288
29. Sicras-Mainar A., Velasco-Velasco S., Llopart-López J.R., Navarro-Artieda R., and de Haro-Martí L. Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population. Aten. Primaria 39 (2007) 547-555
30. Sinclair A.J., Conroy S.P., and Bayer A.J. Impact of diabetes on physical function in older people. Diabetes Care 31 (2008) 233-235
31. Wouters E.F. Chronic obstructive pulmonary disease. Systemic effects of COPD. Thorax 57 (2002) 1067-1070
32. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc. Nutr. Soc. 58 (1999) 321-328
33. Schols A.M. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur. Respir. J. 46 Suppl. (2003) 81S-86S
34. Mador M.J. Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166 (2002) 787-789
35. Schols A.M., Buurman W.A., Staal van den Brekel A.J., Dentener M.A., and Wouters E.F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (1996) 819-824
36. Vermeeren M.A., Schols A.M., and Wouters E.F. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur. Respir. J. 10 (1997) 2264-2269
37. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343 (2000) 269-280
38. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J. Biochem. Mol. Biol. 36 (2003) 95-109
39. Rahman I., Gilmour P.S., Jimenez L.A., and MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem. (2002) 234-248
40. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., and Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 17 (2001) 189-212
41. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J. Clin. Invest. 114 (2004) 1187-1195
42. Venmans L.M., Bont J., Gorter K.J., Verheij T.J., Rutten G.E., and Hak E. Prediction of complicated lower respiratory tract infections in older patients with diabetes. Br. J. Gen. Pract. 58 (2008) 564-568
43. Geerlings S.E., and Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM). FEMS. Immunol. Med. Microbiol. 26 (1999) 259-265
44. Gudmundsson G., Gislason T., Lindberg E., Hallin R., Ulrik ChS, Brondum E., et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir. Res. 7 (2006) 109
45. Almagro P., Calbo E., Ochoa de Echagen A., Barreiro B., Quintana S., and Heredia J.L./E.-A. Mortality after hospitalization for COPD. Chest 121 (2002) 1441-1448
46. Groenewegen K.H., Schols A.M., and Wouters E.F.M. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124 (2003) 459-467
47. Yohannes A.M., Baldwin R.C., and Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing 31 (2002) 137-140
48. Pena V.S., Miravitlles M., Gabriel R., Jimenez-Ruiz C.A., Villasante C., Masa J.F., et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 118 (2000) 981-989
49. Marco J.L., Martin Berra J.C., Corres I.M., Luque D.R., and Zubillaga G.G. Chronic obstructive lung disease in the general population, an epidemiologic study performed in Guipuzcoa. Arch. Bronconeumol. 34 (1998) 23-27
50. Brotons B., Perez J.A., Sanchez-Toril F., Soriano S., Hernandez J., and Belenguer J.L. The prevalence of chronic obstructive pulmonary disease and asthma, a cross-sectional study. Arch. Bronconeumol. 30 (1994) 149-152